Beigene Ltd
ONC326.060USD
-2.650-0.81%
Handelsschluss 09/26, 16:00（ET）Kurse um 15 Minuten verzögert
32.94BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Unternehmen
Unternehmensinformationen
BörsenkürzelONC
Name des UnternehmensBeOne Medicines AG
IPO-datum- -
CEOMr. John Victor Oyler
Anzahl der mitarbeiter11000
WertpapierartOrdinary Share
Geschäftsjahresende- -
Addressec/o BeOne Medicines I GmbH
StadtBASEL
BörseThe Toronto Stock Exchange
LandSwitzerland
Postleitzahl4051
Telefon41616851900
Website
BörsenkürzelONC
IPO-datum- -
CEOMr. John Victor Oyler
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Xiaobin Wu, Ph.D.
Mr. Xiaobin Wu, Ph.D.
President, Chief Operating Officer, General Manager, China
President, Chief Operating Officer, General Manager, China
10.89K
--
Mr. Lai Wang
Mr. Lai Wang
Global Head of R&D
Global Head of R&D
--
--
MR. Aaron Rosenberg
MR. Aaron Rosenberg
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Olivier Brandicourt, M.D.
Dr. Olivier Brandicourt, M.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Giancarlo Benelli
Mr. Giancarlo Benelli
Senior Vice President, Head of Europe
Senior Vice President, Head of Europe
--
--
Mr. Chan Lee, J.D.
Mr. Chan Lee, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
--
--
Ms. Shalini Sharp
Ms. Shalini Sharp
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Xiaodong Wang, Ph.D.
Dr. Xiaodong Wang, Ph.D.
Co-Founder, Non-Executive Director
Co-Founder, Non-Executive Director
--
--
Dr. Han (Margaret) Dugan, M.D.
Dr. Han (Margaret) Dugan, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. John Victor Oyler
Mr. John Victor Oyler
Co-Founder, Executive Chairman of the Board, Chief Executive Officer
Co-Founder, Executive Chairman of the Board, Chief Executive Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Xiaobin Wu, Ph.D.
Mr. Xiaobin Wu, Ph.D.
President, Chief Operating Officer, General Manager, China
President, Chief Operating Officer, General Manager, China
10.89K
--
Mr. Lai Wang
Mr. Lai Wang
Global Head of R&D
Global Head of R&D
--
--
MR. Aaron Rosenberg
MR. Aaron Rosenberg
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Olivier Brandicourt, M.D.
Dr. Olivier Brandicourt, M.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Giancarlo Benelli
Mr. Giancarlo Benelli
Senior Vice President, Head of Europe
Senior Vice President, Head of Europe
--
--
Mr. Chan Lee, J.D.
Mr. Chan Lee, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
--
--
Umsatzaufteilung
Währung: USDAktualisiert: Sun, Jul 6
Währung: USDAktualisiert: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Product
1.09B
97.61%
BRUKINSA
791.66M
70.86%
Tislelizumab
171.16M
15.32%
XGEVA
70.42M
6.30%
BLINCYTO
23.91M
2.14%
Andere
-1.03B
-92.23%
Nach RegionUSD
Name
Umsatz
Anteil
United States
567.21M
50.77%
China
399.59M
35.76%
Europe
118.55M
10.61%
ROW
31.92M
2.86%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Product
1.09B
97.61%
BRUKINSA
791.66M
70.86%
Tislelizumab
171.16M
15.32%
XGEVA
70.42M
6.30%
BLINCYTO
23.91M
2.14%
Andere
-1.03B
-92.23%
Aktionärsstatistik
Aktualisiert: 18 hours ago
Aktualisiert: 18 hours ago
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Amgen Inc
17.27%
Baker Bros. Advisors LP
8.02%
PRIMECAP Management Company
4.64%
Capital International Investors
4.45%
Fidelity Management & Research Company LLC
3.11%
Andere
62.50%
Aktionäre
Aktionäre
Anteil
Amgen Inc
17.27%
Baker Bros. Advisors LP
8.02%
PRIMECAP Management Company
4.64%
Capital International Investors
4.45%
Fidelity Management & Research Company LLC
3.11%
Andere
62.50%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
18.07%
Corporation
17.28%
Hedge Fund
9.62%
Investment Advisor/Hedge Fund
4.28%
Sovereign Wealth Fund
1.13%
Research Firm
0.63%
Bank and Trust
0.07%
Pension Fund
0.05%
Family Office
0.02%
Andere
48.85%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
558
63.29M
57.54%
+456.15K
2025Q1
585
69.06M
63.84%
+3.36M
2024Q4
575
70.01M
71.38%
+1.65M
2024Q3
603
67.03M
68.90%
-2.04M
2024Q2
601
66.99M
69.35%
-2.19M
2024Q1
621
66.56M
67.86%
-955.35K
2023Q4
626
65.12M
66.49%
-3.71M
2023Q3
632
67.27M
67.88%
-2.05M
2023Q2
655
66.79M
67.58%
-3.13M
2023Q1
655
67.68M
71.16%
-4.10M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Amgen Inc
18.94M
17.28%
--
--
Feb 20, 2025
Baker Bros. Advisors LP
8.80M
8.03%
--
--
Mar 31, 2025
PRIMECAP Management Company
5.06M
4.61%
-43.40K
-0.85%
Mar 31, 2025
Capital International Investors
5.09M
4.64%
-1.02M
-16.72%
Mar 31, 2025
Fidelity Management & Research Company LLC
3.36M
3.07%
+1.58M
+88.38%
Mar 31, 2025
HHLR Advisors, Ltd.
1.03M
0.94%
--
--
May 09, 2025
Temasek Holdings Pte. Ltd.
993.75K
0.91%
-531.58K
-34.85%
Mar 31, 2025
T. Rowe Price International Ltd
1.30M
1.19%
-143.22K
-9.92%
Mar 31, 2025
Citadel Advisors LLC
982.16K
0.9%
+665.05K
+209.72%
Mar 31, 2025
Invus Public Equities Advisors, LLC
498.69K
0.46%
-155.03K
-23.72%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Sep 6
Aktualisiert: Sat, Sep 6
Name
Anteil
Goldman Sachs MarketBeta Emerging Markets Eqty ETF
0%
Goldman Sachs Innovate Equity ETF
0%
Goldman Sachs MarketBeta Total Internatl Eqty ETF
0%
T Rowe Price Small-Mid Cap ETF
0%
T Rowe Price US Equity Research ETF
0%
Invesco ESG NASDAQ Next Gen 100 ETF
0%
Invesco NASDAQ Next Gen 100 ETF
0%
Goldman Sachs MarketBeta Emerging Markets Eqty ETF
Anteil0%
Goldman Sachs Innovate Equity ETF
Anteil0%
Goldman Sachs MarketBeta Total Internatl Eqty ETF
Anteil0%
T Rowe Price Small-Mid Cap ETF
Anteil0%
T Rowe Price US Equity Research ETF
Anteil0%
Invesco ESG NASDAQ Next Gen 100 ETF
Anteil0%
Invesco NASDAQ Next Gen 100 ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
